Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Multimodal Signatures of Tau Pathology, Neuronal Fiber Integrity, and Functional Connectivity in Traumatic Brain Injury.

Wooten DW, Ortiz-Terán L, Zubcevik N, Zhang X, Huang C, Sepulcre J, Atassi N, Johnson K, Zafonte R, El Fakhri G.

J Neurotrauma. 2019 Jun 18. doi: 10.1089/neu.2018.6178. [Epub ahead of print]

PMID:
31210098
2.

Adjusted Cost Analysis of Video Televisits for the Care of People with ALS.

Paganoni S, Van De Rijn M, Drake K, Burke K, Doyle M, Ellrodt AS, Nicholson K, Atassi N, De Marchi F, Babu S, Estrada J, Schwamm LH, Berry JD.

Muscle Nerve. 2019 May 28. doi: 10.1002/mus.26606. [Epub ahead of print]

PMID:
31136007
3.

A Phase I/II Placebo-Controlled Randomized Pilot Clinical Trial of Recombinant Deoxyribonuclease (DNase) Eye Drops Use in Patients With Dry Eye Disease.

Mun C, Gulati S, Tibrewal S, Chen YF, An S, Surenkhuu B, Raju I, Buwick M, Ahn A, Kwon JE, Atassi N, Pradeep A, Rondelli D, Jain S.

Transl Vis Sci Technol. 2019 May 2;8(3):10. doi: 10.1167/tvst.8.3.10. eCollection 2019 May.

4.

Positron Emission Tomography Molecular Imaging Biomarkers for Amyotrophic Lateral Sclerosis.

Chew S, Atassi N.

Front Neurol. 2019 Mar 1;10:135. doi: 10.3389/fneur.2019.00135. eCollection 2019. Review.

5.

Stratification of amyotrophic lateral sclerosis patients: a crowdsourcing approach.

Kueffner R, Zach N, Bronfeld M, Norel R, Atassi N, Balagurusamy V, Di Camillo B, Chio A, Cudkowicz M, Dillenberger D, Garcia-Garcia J, Hardiman O, Hoff B, Knight J, Leitner ML, Li G, Mangravite L, Norman T, Wang L; ALS Stratification Consortium, Xiao J, Fang WC, Peng J, Yang C, Chang HJ, Stolovitzky G.

Sci Rep. 2019 Jan 24;9(1):690. doi: 10.1038/s41598-018-36873-4.

6.

Provisional best practices guidelines for the evaluation of bulbar dysfunction in amyotrophic lateral sclerosis.

Pattee GL, Plowman EK, Focht Garand KL, Costello J, Brooks BR, Berry JD, Smith RA, Atassi N, Chapin JL, Yunusova Y, McIlduff CE, Young E, Macklin EA, Locatelli ER, Silani V, Heitzman D, Wymer J, Goutman SA, Gelinas DF, Perry B, Nalipinski P, Stipancic K, O'Brien M, Sullivan SL, Pioro EP, Gargiulo G, Green JR; Contributing Members of the NEALS Bulbar Subcommittee.

Muscle Nerve. 2019 May;59(5):531-536. doi: 10.1002/mus.26408. Epub 2019 Jan 22.

PMID:
30620104
7.

A pilot trial of RNS60 in amyotrophic lateral sclerosis.

Paganoni S, Alshikho MJ, Luppino S, Chan J, Pothier L, Schoenfeld D, Andres PL, Babu S, Zürcher NR, Loggia ML, Barry RL, Luotti S, Nardo G, Trolese MC, Pantalone S, Bendotti C, Bonetto V, De Marchi F, Rosen B, Hooker J, Cudkowicz M, Atassi N.

Muscle Nerve. 2019 Mar;59(3):303-308. doi: 10.1002/mus.26385. Epub 2018 Dec 26.

PMID:
30458059
8.

Integrated imaging of [11C]-PBR28 PET, MR diffusion and magnetic resonance spectroscopy 1H-MRS in amyotrophic lateral sclerosis.

Ratai EM, Alshikho MJ, Zürcher NR, Loggia ML, Cebulla CL, Cernasov P, Reynolds B, Fish J, Seth R, Babu S, Paganoni S, Hooker JM, Atassi N.

Neuroimage Clin. 2018 Aug 9;20:357-364. doi: 10.1016/j.nicl.2018.08.007. eCollection 2018.

9.

When a negative trial in ALS has a positive effect on research.

Atassi N.

Lancet Neurol. 2018 Aug;17(8):653-655. doi: 10.1016/S1474-4422(18)30210-2. Epub 2018 Jun 19. No abstract available.

PMID:
29934197
10.

Long-term Phase 1/2 intraspinal stem cell transplantation outcomes in ALS.

Goutman SA, Brown MB, Glass JD, Boulis NM, Johe K, Hazel T, Cudkowicz M, Atassi N, Borges L, Patil PG, Sakowski SA, Feldman EL.

Ann Clin Transl Neurol. 2018 May 2;5(6):730-740. doi: 10.1002/acn3.567. eCollection 2018 Jun.

11.

Implementing Motor Unit Number Index (MUNIX) in a large clinical trial: Real world experience from 27 centres.

Neuwirth C, Braun N, Claeys KG, Bucelli R, Fournier C, Bromberg M, Petri S, Goedee S, Lenglet T, Leppanen R, Canosa A, Goodman I, Al-Lozi M, Ohkubo T, Hübers A, Atassi N, Abrahao A, Funke A, Appelfeller M, Tümmler A, Finegan E, Glass JD, Babu S, Ladha SS, Kwast-Rabben O, Juntas-Morales R, Coffey A, Chaudhry V, Vu T, Saephanh C, Newhard C, Zakrzewski M, Rosier E, Hamel N, Raheja D, Raaijman J, Ferguson T, Weber M.

Clin Neurophysiol. 2018 Aug;129(8):1756-1762. doi: 10.1016/j.clinph.2018.04.614. Epub 2018 May 3.

PMID:
29803404
12.

Integrated magnetic resonance imaging and [11 C]-PBR28 positron emission tomographic imaging in amyotrophic lateral sclerosis.

Alshikho MJ, Zürcher NR, Loggia ML, Cernasov P, Reynolds B, Pijanowski O, Chonde DB, Izquierdo Garcia D, Mainero C, Catana C, Chan J, Babu S, Paganoni S, Hooker JM, Atassi N.

Ann Neurol. 2018 Jun;83(6):1186-1197. doi: 10.1002/ana.25251.

13.

Magnetic resonance imaging based anatomical assessment of tongue impairment due to amyotrophic lateral sclerosis: A preliminary study.

Lee E, Xing F, Ahn S, Reese TG, Wang R, Green JR, Atassi N, Wedeen VJ, El Fakhri G, Woo J.

J Acoust Soc Am. 2018 Apr;143(4):EL248. doi: 10.1121/1.5030134.

14.

Strain Map of the Tongue in Normal and ALS Speech Patterns from Tagged and Diffusion MRI.

Xing F, Prince JL, Stone M, Reese TG, Atassi N, Wedeen VJ, El Fakhri G, Woo J.

Proc SPIE Int Soc Opt Eng. 2018 Feb;10574. pii: 1057411. doi: 10.1117/12.2293028. Epub 2018 Mar 2.

15.

Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS.

Benatar M, Wuu J, Andersen PM, Atassi N, David W, Cudkowicz M, Schoenfeld D.

Neurology. 2018 Feb 13;90(7):e565-e574. doi: 10.1212/WNL.0000000000004960. Epub 2018 Jan 24.

16.

Head-to-Head Comparison of 11C-PBR28 and 18F-GE180 for Quantification of the Translocator Protein in the Human Brain.

Zanotti-Fregonara P, Pascual B, Rizzo G, Yu M, Pal N, Beers D, Carter R, Appel SH, Atassi N, Masdeu JC.

J Nucl Med. 2018 Aug;59(8):1260-1266. doi: 10.2967/jnumed.117.203109. Epub 2018 Jan 18.

PMID:
29348317
17.

Nonmotor manifestations in ALS patients with tracheostomy and invasive ventilation.

Atassi N.

Muscle Nerve. 2018 May;57(5):699-700. doi: 10.1002/mus.26068. Epub 2018 Feb 19. No abstract available.

PMID:
29342311
18.

Longitudinal modeling to predict vital capacity in amyotrophic lateral sclerosis.

Jahandideh S, Taylor AA, Beaulieu D, Keymer M, Meng L, Bian A, Atassi N, Andrews J, Ennist DL.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 May;19(3-4):294-302. doi: 10.1080/21678421.2017.1418003. Epub 2017 Dec 20.

PMID:
29260584
19.

Best practices protocol for the evaluation of bulbar dysfunction: summary recommendations from the NEALS bulbar subcommittee symposium.

Pattee GL, Plowman EK, Brooks BR, Berry JD, Atassi N, Chapin JL, Garand K, Yunusova Y, Mcilduff CE, Young E, Costello JM, Macklin EA, Locatelli ER, Silani V, Heitzman D, Wymer J, Goutman SA, Gelinas DF, Smith R, Perry B, Nalipinski P, Stipancic K, O'Brien M, Sullivan SL, Green J; CONTRIBUTING MEMBERS OF THE NEALS BULBAR SUBCOMMITTEE.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 May;19(3-4):311-312. doi: 10.1080/21678421.2017.1404109. Epub 2017 Dec 5.

PMID:
29205054
20.

A randomized controlled trial of resistance and endurance exercise in amyotrophic lateral sclerosis.

Clawson LL, Cudkowicz M, Krivickas L, Brooks BR, Sanjak M, Allred P, Atassi N, Swartz A, Steinhorn G, Uchil A, Riley KM, Yu H, Schoenfeld DA, Maragakis NJ; neals consortium.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 May;19(3-4):250-258. doi: 10.1080/21678421.2017.1404108. Epub 2017 Nov 30.

PMID:
29191052
21.

Imaging of glia activation in people with primary lateral sclerosis.

Paganoni S, Alshikho MJ, Zürcher NR, Cernasov P, Babu S, Loggia ML, Chan J, Chonde DB, Garcia DI, Catana C, Mainero C, Rosen BR, Cudkowicz ME, Hooker JM, Atassi N.

Neuroimage Clin. 2017 Oct 25;17:347-353. doi: 10.1016/j.nicl.2017.10.024. eCollection 2018.

22.

PET Imaging of Human Brown Adipose Tissue with the TSPO Tracer [11C]PBR28.

Ran C, Albrecht DS, Bredella MA, Yang J, Yang J, Liang SH, Cypess AM, Loggia ML, Atassi N, Moore A.

Mol Imaging Biol. 2018 Apr;20(2):188-193. doi: 10.1007/s11307-017-1129-z.

23.

Analysis of Participant Withdrawal in Huntington Disease Clinical Trials.

Banno H, Andrzejewski KL, McDermott MP, Murphy A, Majumder M, de Blieck EA, Auinger P, Cudkowicz ME, Atassi N.

J Huntingtons Dis. 2017;6(4):371. doi: 10.3233/JHD-179002. No abstract available.

PMID:
28922164
24.

Causal inference methods to study gastric tube use in amyotrophic lateral sclerosis.

McDonnell E, Schoenfeld D, Paganoni S, Atassi N.

Neurology. 2017 Oct 3;89(14):1483-1489. doi: 10.1212/WNL.0000000000004534. Epub 2017 Sep 1.

25.

Urate levels predict survival in amyotrophic lateral sclerosis: Analysis of the expanded Pooled Resource Open-Access ALS clinical trials database.

Paganoni S, Nicholson K, Chan J, Shui A, Schoenfeld D, Sherman A, Berry J, Cudkowicz M, Atassi N; Pooled Resource Open-Access ALS Clinical Trials Consortium.

Muscle Nerve. 2018 Mar;57(3):430-434. doi: 10.1002/mus.25950. Epub 2017 Sep 21.

26.

Pseudoreference Regions for Glial Imaging with 11C-PBR28: Investigation in 2 Clinical Cohorts.

Albrecht DS, Normandin MD, Shcherbinin S, Wooten DW, Schwarz AJ, Zürcher NR, Barth VN, Guehl NJ, Akeju O, Atassi N, Veronese M, Turkheimer F, Hooker JM, Loggia ML.

J Nucl Med. 2018 Jan;59(1):107-114. doi: 10.2967/jnumed.116.178335. Epub 2017 Aug 17.

27.

Functional Decline is Associated with Hopelessness in Amyotrophic Lateral Sclerosis (ALS).

Paganoni S, McDonnell E, Schoenfeld D, Yu H, Deng J, Atassi H, Sherman A, Yerramilli-Rao P, Cudkowicz M, Atassi N.

J Neurol Neurophysiol. 2017 Apr;8(2). pii: 423. doi: 10.4172/2155-9562.1000423. Epub 2017 Apr 29.

28.

Analysis of Participant Withdrawal in Huntington Disease Clinical Trials.

Banno H, Andrzejewski KL, McDermott MP, Murphy A, Majumder M, de Blieck EA, Auinger P, Cudkowicz ME, Atassi N.

J Huntingtons Dis. 2017;6(2):149-156. doi: 10.3233/JHD-170246. Erratum in: J Huntingtons Dis. 2017;6(4):371.

29.

Phase IIa trial of fingolimod for amyotrophic lateral sclerosis demonstrates acceptable acute safety and tolerability.

Berry JD, Paganoni S, Atassi N, Macklin EA, Goyal N, Rivner M, Simpson E, Appel S, Grasso DL, Mejia NI, Mateen F, Gill A, Vieira F, Tassinari V, Perrin S.

Muscle Nerve. 2017 Dec;56(6):1077-1084. doi: 10.1002/mus.25733. Epub 2017 Aug 29.

30.

Improving symptom management for people with amyotrophic lateral sclerosis.

Nicholson K, Murphy A, McDonnell E, Shapiro J, Simpson E, Glass J, Mitsumoto H, Forshew D, Miller R, Atassi N.

Muscle Nerve. 2018 Jan;57(1):20-24. doi: 10.1002/mus.25712. Epub 2017 Jul 1.

PMID:
28561886
31.

Ultra high-field (7tesla) magnetic resonance spectroscopy in Amyotrophic Lateral Sclerosis.

Atassi N, Xu M, Triantafyllou C, Keil B, Lawson R, Cernasov P, Ratti E, Long CJ, Paganoni S, Murphy A, Salibi N, Seethamraju R, Rosen B, Ratai EM.

PLoS One. 2017 May 12;12(5):e0177680. doi: 10.1371/journal.pone.0177680. eCollection 2017.

32.

Glial activation colocalizes with structural abnormalities in amyotrophic lateral sclerosis.

Alshikho MJ, Zürcher NR, Loggia ML, Cernasov P, Chonde DB, Izquierdo Garcia D, Yasek JE, Akeju O, Catana C, Rosen BR, Cudkowicz ME, Hooker JM, Atassi N.

Neurology. 2016 Dec 13;87(24):2554-2561. Epub 2016 Nov 11.

33.

Intraspinal stem cell transplantation for amyotrophic lateral sclerosis: Ready for efficacy clinical trials?

Atassi N, Beghi E, Blanquer M, Boulis NM, Cantello R, Caponnetto C, Chiò A, Dunnett SB, Feldman EL, Vescovi A, Mazzini L; attendees of the International Workshop on Progress in Stem Cells Research for ALS/MND.

Cytotherapy. 2016 Dec;18(12):1471-1475. doi: 10.1016/j.jcyt.2016.08.005. Epub 2016 Oct 6.

34.

Transplantation of spinal cord-derived neural stem cells for ALS: Analysis of phase 1 and 2 trials.

Glass JD, Hertzberg VS, Boulis NM, Riley J, Federici T, Polak M, Bordeau J, Fournier C, Johe K, Hazel T, Cudkowicz M, Atassi N, Borges LF, Rutkove SB, Duell J, Patil PG, Goutman SA, Feldman EL.

Neurology. 2016 Jul 26;87(4):392-400. doi: 10.1212/WNL.0000000000002889. Epub 2016 Jun 29. Erratum in: Neurology. 2017 Aug 1;89(5):521.

35.

Defining SOD1 ALS natural history to guide therapeutic clinical trial design.

Bali T, Self W, Liu J, Siddique T, Wang LH, Bird TD, Ratti E, Atassi N, Boylan KB, Glass JD, Maragakis NJ, Caress JB, McCluskey LF, Appel SH, Wymer JP, Gibson S, Zinman L, Mozaffar T, Callaghan B, McVey AL, Jockel-Balsarotti J, Allred P, Fisher ER, Lopate G, Pestronk A, Cudkowicz ME, Miller TM.

J Neurol Neurosurg Psychiatry. 2017 Feb;88(2):99-105. doi: 10.1136/jnnp-2016-313521. Epub 2016 Jun 3.

36.

First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer's disease.

Delnomdedieu M, Duvvuri S, Li DJ, Atassi N, Lu M, Brashear HR, Liu E, Ness S, Kupiec JW.

Alzheimers Res Ther. 2016 Mar 1;8(1):12. doi: 10.1186/s13195-016-0177-y.

37.

A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progression.

Weiss MD, Macklin EA, Simmons Z, Knox AS, Greenblatt DJ, Atassi N, Graves M, Parziale N, Salameh JS, Quinn C, Brown RH Jr, Distad JB, Trivedi J, Shefner JM, Barohn RJ, Pestronk A, Swenson A, Cudkowicz ME; Mexiletine ALS Study Group.

Neurology. 2016 Apr 19;86(16):1474-81. doi: 10.1212/WNL.0000000000002507. Epub 2016 Feb 24.

38.

Primary Lateral Sclerosis and Early Upper Motor Neuron Disease: Characteristics of a Cross-Sectional Population.

Fournier CN, Murphy A, Loci L, Mitsumoto H, Lomen-Hoerth C, Kisanuki Y, Simmons Z, Maragakis NJ, McVey AL, Al-Lahham T, Heiman-Patterson TD, Andrews J, McDonnell E, Cudkowicz M, Atassi N.

J Clin Neuromuscul Dis. 2016 Mar;17(3):99-105. doi: 10.1097/CND.0000000000000102.

39.

ALS biomarkers for therapy development: State of the field and future directions.

Benatar M, Boylan K, Jeromin A, Rutkove SB, Berry J, Atassi N, Bruijn L.

Muscle Nerve. 2016 Feb;53(2):169-82. doi: 10.1002/mus.24979. Epub 2015 Dec 29. Review.

40.

Pre-morbid type 2 diabetes mellitus is not a prognostic factor in amyotrophic lateral sclerosis.

Paganoni S, Hyman T, Shui A, Allred P, Harms M, Liu J, Maragakis N, Schoenfeld D, Yu H, Atassi N, Cudkowicz M, Miller TM.

Muscle Nerve. 2015 Sep;52(3):339-43. doi: 10.1002/mus.24688. Epub 2015 Jun 1.

41.

Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: assessed with [(11)C]-PBR28.

Zürcher NR, Loggia ML, Lawson R, Chonde DB, Izquierdo-Garcia D, Yasek JE, Akeju O, Catana C, Rosen BR, Cudkowicz ME, Hooker JM, Atassi N.

Neuroimage Clin. 2015 Jan 19;7:409-14. doi: 10.1016/j.nicl.2015.01.009. eCollection 2015.

42.

Disease burden in upper motor neuron syndromes: a survey of patient perspectives.

Andrews JA, Paganoni S, Braastad C, Cudkowicz M, Atassi N.

J Clin Neuromuscul Dis. 2014 Dec;16(2):104-5. doi: 10.1097/CND.0000000000000051. No abstract available.

43.

The PRO-ACT database: design, initial analyses, and predictive features.

Atassi N, Berry J, Shui A, Zach N, Sherman A, Sinani E, Walker J, Katsovskiy I, Schoenfeld D, Cudkowicz M, Leitner M.

Neurology. 2014 Nov 4;83(19):1719-25. doi: 10.1212/WNL.0000000000000951. Epub 2014 Oct 8.

44.

Neuroprotective agents target molecular mechanisms of disease in ALS.

Zhu Y, Fotinos A, Mao LL, Atassi N, Zhou EW, Ahmad S, Guan Y, Berry JD, Cudkowicz ME, Wang X.

Drug Discov Today. 2015 Jan;20(1):65-75. doi: 10.1016/j.drudis.2014.08.016. Epub 2014 Sep 6. Review.

PMID:
25205348
45.

Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS).

Paganoni S, Macklin EA, Lee A, Murphy A, Chang J, Zipf A, Cudkowicz M, Atassi N.

Amyotroph Lateral Scler Frontotemporal Degener. 2014 Sep;15(5-6):453-6. doi: 10.3109/21678421.2014.903974. Epub 2014 Jul 1.

46.

Feedback interaction of research, advocacy, and clinical care applied to ALS research in South America.

Bucheli ME, Calderón A, Chicaiza D, Franco C, López R, Digga E, Atassi N, Salameh J, Berry JD.

Neurology. 2013 Nov 26;81(22):1959-61. doi: 10.1212/01.wnl.0000436610.28210.a5.

47.

Amyotrophic lateral sclerosis: analysis of ALS cases in a predominantly admixed population of Ecuador.

Bucheli M, Andino A, Montalvo M, Cruz J, Atassi N, Berry J, Salameh J.

Amyotroph Lateral Scler Frontotemporal Degener. 2014 Mar;15(1-2):106-13. doi: 10.3109/21678421.2013.852590. Epub 2013 Nov 18.

PMID:
24245684
48.

Functional and oncological outcomes of patients aged <50 years treated with radical prostatectomy for localised prostate cancer in a European population.

Becker A, Tennstedt P, Hansen J, Trinh QD, Kluth L, Atassi N, Schlomm T, Salomon G, Haese A, Budaeus L, Michl U, Heinzer H, Huland H, Graefen M, Steuber T.

BJU Int. 2014 Jul;114(1):38-45. doi: 10.1111/bju.12407. Epub 2013 Dec 2.

49.

Analysis of start-up, retention, and adherence in ALS clinical trials.

Atassi N, Yerramilli-Rao P, Szymonifka J, Yu H, Kearney M, Grasso D, Deng J, Levine-Weinberg M, Shapiro J, Lee A, Joseph L, Macklin EA, Cudkowicz ME.

Neurology. 2013 Oct 8;81(15):1350-5. doi: 10.1212/WNL.0b013e3182a823e0. Epub 2013 Sep 4. Review.

50.

Post-lumbar puncture headache is reduced with use of atraumatic needles in ALS.

Quinn C, Macklin EA, Atassi N, Bowser R, Boylan K, Cudkowicz M, Fournier C, Ladha SS, Lacomis D, Berry J.

Amyotroph Lateral Scler Frontotemporal Degener. 2013 Dec;14(7-8):632-4. doi: 10.3109/21678421.2013.808227. Epub 2013 Jul 8. No abstract available.

PMID:
23834161

Supplemental Content

Loading ...
Support Center